中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共39条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Li, Ning;  Zhang, Youzhong;  Wang, Jing;  Zhu, Jianqing;  Wang, Li;  Wu, Xiaohua;  Yao, Desheng;  Wu, Qiang;  Liu, Jihong;  Tang, Junying;  Yin, Rutie;  Lou, Ge;  An, Ruifang;  Zhang, Guonan;  Xia, Xiaoping;  Li, Qingshui;  Zhu, Yaping;  Zheng, Hong;  Yang, Xinfeng;  Hu, Yuanjing;  Zhang, Xin;  Hao, Min;  Huang, Yi;  Lin, Zhongqiu;  Wang, Dong;  Guo, Xiaoqing;  Yao, Shuzhong;  Wan, Xiaoyun;  Zhou, Huaijun;  Yao, Liangqing;  Yang, Xielan;  Cui, Heng;  Meng, Yuanguang;  Zhang, Songling;  Qu, Jing;  Zhang, Ben;  Zou, Jianjun;  Wu, Lingying
收藏  |  浏览/下载：28/0  |  提交时间：2022/12/22
Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Ma, Ding;  Gao, Qing-Lei;  Zhu, Jianqing;  Zhao, Weidong;  Huang, Yi;  An, Ruifang;  Zheng, Hong;  Qu, Pengpeng;  Wang, Li;  Zhou, Qi;  Wang, Danbo;  Lou, Ge;  Wang, Jing;  Low, John;  Kong, Beihua;  Yin, Rutie;  Xie, Xing;  Liu, Jihong;  Sun, Wei;  Zang, Rongyu
收藏  |  浏览/下载：26/0  |  提交时间：2022/12/23
Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Chen, Zhanhong;  Wang, Xiaojia;  Huang, Jian;  Zheng, Yabing;  Shao, Xiying;  Cao, Wenming;  Chen, Junqing;  Ye, Weiwu;  Ping, Huang;  Li, Guangliang;  Lei, Lei;  Shi, Lei;  Huang, Yuan;  Zou, Weibin;  Wang, Rong;  Shen, Xia-Bo;  Lou, Caijin
收藏  |  浏览/下载：27/0  |  提交时间：2022/12/23
A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Yu, Pengfei;  Du, Yian;  Xu, Zhiyuan;  Yang, Litao;  Ying, Jieer;  Wang, Yongxiang;  Chen, Ping;  Wei, Yunhai;  Xu, Hongtao;  Xu, Nong;  Cheng, Xiangdong
收藏  |  浏览/下载：40/0  |  提交时间：2022/12/23
A novel patient-derived organoid model for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy for screening personalized drugs. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Liu, Feiyang;  Ma, Dandan;  Liu, Qingsong;  Qi, Xiaowei
收藏  |  浏览/下载：30/0  |  提交时间：2022/12/23
Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Yin, Rutie;  Li, Ning;  Wu, Lingying;  Wang, Jing;  Zhu, Jianqing;  Pan, Lingya;  Kong, Beihua;  Zheng, Hong;  Liu, Jihong;  Wu, Xiaohua;  Wang, Li;  Huang, Yi;  Wang, Ke;  Zou, Dongling;  Zhao, Hongqin;  Wang, Chunyan;  Lu, Weiguo;  Zhen, Xiaoa;  Hang, Wenzhao;  Hou, Jianmei
收藏  |  浏览/下载：33/0  |  提交时间：2022/12/23
BRCANet: A deep hybrid network in predicting BRCA1/2 gene mutation of breast cancer with dynamic contrast-enhanced breast MRI. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Cao, Wen-Ming;  Wang, Xiaojia;  Liu, Jian;  Wang, Lili;  Zhang, Xiaodong;  Pan, Jiani;  Ye, Weiwu;  Chen, Zhanhong;  Zheng, Yabing;  Shao, Xiying;  Xu, Yuanji
收藏  |  浏览/下载：36/0  |  提交时间：2022/12/23
Platelet-to-Lymphocyte ratio (PLR) as a predictive marker in HER2 positive metastatic breast cancer patients treated with first-line trastuzumab therapy. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Fang, Zi-Ru;  Shen, Xia-Bo;  Wu, Jia-Yi;  Chen, Ke-Yu;  Shao, Xi-Ying;  Wang, Xiaojia
收藏  |  浏览/下载：40/0  |  提交时间：2022/12/23
Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Shen, Xia-Bo;  Wu, Jia-Yi;  Chen, Ke-Yu;  Fang, Zi-Ru;  Li, Guang-Liang;  Zou, Wei-Bin;  Wang, Xiaojia;  Shao, Xi-Ying
收藏  |  浏览/下载：29/0  |  提交时间：2022/12/23
A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC). 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Wang, Jing;  Lou, Hanmei;  Cai, Hong-Bing;  Huang, Xin;  Li, Guiling;  Wang, Li;  Liu, Ting;  Liu, Wei;  Li, Baiyong;  Xia, Yu
收藏  |  浏览/下载：33/0  |  提交时间：2022/12/23